

# Shashank Tripathi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2996039/publications.pdf>

Version: 2024-02-01

26  
papers

3,473  
citations

430874

18  
h-index

552781

26  
g-index

29  
all docs

29  
docs citations

29  
times ranked

7787  
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta- and Orthogonal Integration of Influenza Omics Data Defines a Role for UBR4 in Virus Budding. <i>Cell Host and Microbe</i> , 2015, 18, 723-735.	11.0	868
2	Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling. <i>Cell Host and Microbe</i> , 2016, 19, 882-890.	11.0	658
3	Enhancement of Zika virus pathogenesis by preexisting ant flavivirus immunity. <i>Science</i> , 2017, 356, 175-180.	12.6	453
4	Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. <i>Nature Microbiology</i> , 2017, 2, 17037.	13.3	292
5	Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis. <i>Cell</i> , 2018, 175, 1931-1945.e18.	28.9	252
6	A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses. <i>PLoS Pathogens</i> , 2017, 13, e1006258.	4.7	200
7	An Immunocompetent Mouse Model of Zika Virus Infection. <i>Cell Host and Microbe</i> , 2018, 23, 672-685.e6.	11.0	192
8	Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. <i>Immunity</i> , 2016, 44, 46-58.	14.3	110
9	The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response. <i>PLoS Pathogens</i> , 2019, 15, e1007634.	4.7	67
10	Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 580096.	3.9	66
11	Influenza virus repurposes the antiviral protein IFIT2 to promote translation of viral mRNAs. <i>Nature Microbiology</i> , 2020, 5, 1490-1503.	13.3	45
12	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. <i>ACS Infectious Diseases</i> , 2021, 7, 2546-2564.	3.8	34
13	Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2. <i>ELife</i> , 2022, 11, .	6.0	28
14	Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples. <i>EBioMedicine</i> , 2021, 70, 103525.	6.1	27
15	Systems-based analysis of RIG-I-dependent signalling identifies KHSRP as an inhibitor of RIG-I receptor activation. <i>Nature Microbiology</i> , 2017, 2, 17022.	13.3	25
16	Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy. <i>Nature Microbiology</i> , 2021, 6, 1319-1333.	13.3	23
17	Interplay between influenza A virus and host factors: targets for antiviral intervention. <i>Archives of Virology</i> , 2015, 160, 1877-1891.	2.1	21
18	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1275-1298.	4.4	21

#	ARTICLE	IF	CITATIONS
19	Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1247-1258.	4.1	20
20	Moving from Empirical to Rational Vaccine Design in the "Omics" Era. <i>Vaccines</i> , 2019, 7, 89.	4.4	19
21	A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 765211.	4.8	16
22	Specific Mutations in the PB2 Protein of Influenza A Virus Compensate for the Lack of Efficient Interferon Antagonism of the NS1 Protein of Bat Influenza A-Like Viruses. <i>Journal of Virology</i> , 2018, 92, .	3.4	11
23	Antiviral innate immunity through the lens of systems biology. <i>Virus Research</i> , 2016, 218, 10-17.	2.2	10
24	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0012321.	13.6	10
25	Live Visualization of Hemagglutinin Dynamics during Infection by Using a Novel Reporter Influenza A Virus. <i>Viruses</i> , 2020, 12, 687.	3.3	2
26	INNATE IMMUNE SUBVERSION STRATEGIES OF HUMAN FLAVIVIRUSES. <i>Critical Reviews in Immunology</i> , 2021, 41, 27-42.	0.5	1